【Abstract】Purpose To observe clinical effect of DNA immunoadsorption for the treatment of lupus nephritis. Methods We selected 32 patients with active lupus nephritis, and divided them equally into conventional treatment group and immunoadsorption group. For conventional treatment group, glucocorticoids (prednisolone) and immunosuppressive drugs (cyclophosphamide) were used; for immunoadsorption group, blood DNA immunoadsorption therapy was performed once half a month for 6 times in addition to the conventional therapy. Blood samples were collected before and after immunoadsorption to evaluate its clearance to antinuclear antibody (ANA) and anti-double-stranded DNA antibody (anti-ds-DNA), and its effect on blood routine examinations, erythrocyte sedimentation rate, immunoglubulins, complements and renal function. Clinical presentations were also recorded. Results In immunoadsorption group after the treatment, symptoms and signs improved significantly, ANA and anti-ds-DNA decreased remarkably (for ANA, from 1:2000 to 1:300, P＜0.001; for anti-ds-DNA, from 36.5±10.4 to 19.4±10.3 IU/ml), immunoglobulins also decreased significantly (P＜0.05), but blood routine examinations, erythrocyte sedimentation rate and complements remained unchanged. Conclusions DNA immunoadsorption is effective for the treatment of lupus nephritis. It improves clinical symptoms with less side-effects, and may become a new approach for the treatment of lupus nephritis.